Intrinsiqs

Is Corvus Pharmaceuticals, Inc. overvalued?

Corvus Pharmaceuticals, Inc. (CRVS) — key valuation metrics and fundamentals.

No verdict
Price
$10.64
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$897.5M
Dividend yield
0.0%
Return on equity
-35.0%
Sector
Healthcare

See the full interactive analysis →

Fair value compares CRVS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.